IDH2 and acute myeloid leukemia: Five [21, 23, 24, 26, 29] articles (5 cohorts) reported the 2-year OS of IDH inhibitors in patients with newly diagnosed IDH-mutated AML, and our pooled 2-year OS rate was 45% [95% CI 0.29–0.62, I2 = 90%].